{"id":2425,"date":"2015-09-11T10:13:03","date_gmt":"2015-09-11T01:13:03","guid":{"rendered":"http:\/\/aihara.la.coocan.jp\/?p=2425"},"modified":"2015-11-08T17:59:01","modified_gmt":"2015-11-08T08:59:01","slug":"%e3%83%af%e3%83%bc%e3%82%af%e3%82%b7%e3%83%a7%e3%83%83%e3%83%97%e3%81%ae%e8%aa%b2%e9%a1%8c%e3%81%a8%e3%83%91%e3%83%8d%e3%83%aa%e3%82%b9%e3%83%88%e3%81%b8%e3%81%ae%e8%b3%aa%e5%95%8f-iom","status":"publish","type":"post","link":"http:\/\/aihara.la.coocan.jp\/?p=2425","title":{"rendered":"\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7\u306e\u8ab2\u984c\u3068\u30d1\u30cd\u30ea\u30b9\u30c8\u3078\u306e\u8cea\u554f (IOM)"},"content":{"rendered":"<p>\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u4f5c\u6210\u306b\u3042\u305f\u3063\u3066\u3001\u30d1\u30cd\u30ea\u30b9\u30c8\u306b\u306f\u5177\u4f53\u7684\u306b\u3069\u306e\u3088\u3046\u306a\u8cea\u554f\u3092\u3059\u3079\u304d\u306a\u306e\u3060\u308d\u3046\u304b\u3002<\/p>\n<p>IOM\u306e\u4fe1\u983c\u3067\u304d\u308b\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\uff08Clinical practice guidelines we can trust\uff09\u306b\u8a18\u8f09\u3055\u308c\u3066\u3044\u308b\u3001\u300c\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7\u306e\u8ab2\u984c\u3068\u30d1\u30cd\u30ea\u30b9\u30c8\u3078\u306e\u8cea\u554f\u300d\uff08Appendix B\uff09\u3067\u30012010\u5e741\u6708\u306eWashington, DC\u3067\u958b\u50ac\u3055\u308c\u305f\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7\u3067\u5229\u7528\u3055\u308c\u305f\u3082\u306e\u304c\u4ee5\u4e0b\u3067\u3059\uff08\u30d5\u30ea\u30fc\u3067\u516c\u958b\u3055\u308c\u3066\u3044\u308b\u3082\u306e\u306a\u306e\u3067\u3001\u7d39\u4ecb\u3057\u307e\u3059\uff09\u3002<\/p>\n<div style=\"font-size: 1.3em\"><b>Questions for the Panelists<\/b><\/div>\n<p><\/p>\n<p><b>What do you believe are the biggest challenges clinical practice guidelines developers\/users face today? For example:<\/b><\/p>\n<ul>\n<li>What do you do when the scientific evidence is absent or poor?<\/li>\n<li>How do you reconcile disagreements in evidence interpretation among guidelines?<\/lI>\n<li>How do guidelines accommodate subgroups (e.g., older populations or persons with multimorbidities) whose treatment outcomes may differ from the average patient?<\/li>\n<li>Are there other challenges you believe are important?<\/li>\n<\/ul>\n<p><\/p>\n<p><b>What topics and\/or processes do you think the committee should consider in deriving quality standards for clinical practice guidelines? For example:<\/b><\/p>\n<ul>\n<li>What should the composition of CPG development panels,in particular the balance of methodologists, topical experts, and consumers, look like? <\/li>\n<li>What methods might be developed for determining which recommendations among those in a guideline should be applied to quality measures or electronic medical record decision prompts?<\/li>\n<li>Is there an available assessment tool that adequately rates both the level of the scientific evidence and strength of clinical recommendations that should be used as standard practice in guideline development?<\/li>\n<li>What administrative (e.g., accreditation) or legal approaches might improve the quality of clinical practice guidelines?<\/li>\n<li>What explicit approaches might harmonize guideline developers and increase guidelines convergence?<\/li>\n<li>What types of strategies might promote greater use of guidelines?<\/li>\n<li>Are there other characteristics of guideline standards you think are important for the committee to consider?<\/li>\n<\/ul>\n<p><\/p>\n<p>\u4e0a\u8a18\u3092\u7ffb\u8a33\u3057\u305f\u3082\u306e\u304c\u3001\u3053\u3061\u3089\u3067\u3059.\uff08<a href=\"http:\/\/www.grade-jpn.com\/iom\/Workshop Agenda and Questions to Panelists-j.docx\">WORD<\/a>\u3001<a href=\"http:\/\/www.grade-jpn.com\/iom\/Workshop Agenda and Questions to Panelists-j.pdf\">PDF<\/a>\uff09\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u4f5c\u6210\u306b\u3042\u305f\u3063\u3066\u3001\u30d1\u30cd\u30ea\u30b9\u30c8\u306b\u306f\u5177\u4f53\u7684\u306b\u3069\u306e\u3088\u3046\u306a\u8cea\u554f\u3092\u3059\u3079\u304d\u306a\u306e\u3060\u308d\u3046\u304b\u3002 IOM\u306e\u4fe1\u983c\u3067\u304d\u308b\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\uff08Clinical practice guidelines we can trust\uff09\u306b\u8a18\u8f09\u3055 [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[357],"tags":[],"_links":{"self":[{"href":"http:\/\/aihara.la.coocan.jp\/index.php?rest_route=\/wp\/v2\/posts\/2425"}],"collection":[{"href":"http:\/\/aihara.la.coocan.jp\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/aihara.la.coocan.jp\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/aihara.la.coocan.jp\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/aihara.la.coocan.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2425"}],"version-history":[{"count":15,"href":"http:\/\/aihara.la.coocan.jp\/index.php?rest_route=\/wp\/v2\/posts\/2425\/revisions"}],"predecessor-version":[{"id":3222,"href":"http:\/\/aihara.la.coocan.jp\/index.php?rest_route=\/wp\/v2\/posts\/2425\/revisions\/3222"}],"wp:attachment":[{"href":"http:\/\/aihara.la.coocan.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2425"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/aihara.la.coocan.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2425"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/aihara.la.coocan.jp\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}